Growth hormone secretagogue receptor of selective ligands for the GHS-R receptor are now available and are being developed for several clinical applications. GHS-R agonists have appetite-stimulating and growth hormone-releasing effects, and are likely to be useful for the treatment of muscle wasting and frailty associated with old-age and degenerative diseases. On the other hand, GHS-R antagonists have anorectic effects and are likely to be useful for the treatment of obesity. Growth hormone secretagogue receptor Growth hormone secretagogue receptor(GHS-R), also known as ghrelin receptor, is a G protein-coupled receptor that binds growth hormone secretagogues (GHSs), such as ghrelin, the "hunger hormone". The role of GHS-R
Growth hormone in sports which the anterior pituitary gland produces excess growth hormone. Human growth hormone occurs naturally in the human body. Use of exogenous human growth hormone (HGH), via injection, was originally for medical purposes until athletes began abusing HGH with the goal of increasing their abilities. Before recombinant human growth hormone (rHGH) was developed in 1981, HGH was only available from cadavers. The arrival of rHGH combined with other peptide hormone advancements has increased the availability of HGH on both the legitimate and black markets. The first description of the use of GM as a doping agent was Dan Duchaine’s “Underground Steroid